Intercept Pharmaceuticals' (ICPT) shares are -30% on what appears to be light volume after the stock skyrocketed 516% on Thursday and Friday following news that a trial for the company's (ICPT) beticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis (NASH) was stopped early due to high efficacy.
Intercept believes that an increase of "bad" cholesterol and decrease of "good" cholesterol in patients will probably be similar to results reported in 2009 regarding a trial of diabetic patients with nonalcoholic fatty liver disease.
The efficacy, safety and tolerability profile of OCA was the basis for the drug's selection for treating NASH.
There is also preclinical evidence that OCA may be "able to shunt excess lipids away from collecting in arteries and other organs, which could also be beneficial," Intercept says. (PR)
Intercept CEO Mark Pruzanski says the company is open to working with a partner to bring OCA to market.